Journal of Thoracic Oncology

Papers
(The H4-Index of Journal of Thoracic Oncology is 64. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Meeting Announcements766
Better Together: Advancing Tobacco Use Treatment and Lung Cancer Screening382
In This Issue/Research Watch/News in Brief326
Board of Directors321
Do We Really Understand the Relationship Between Expression of ACE2 and Coronavirus Disease 2019 Lung Pathophysiology?308
Reply to Kus and Aktas238
New Pulmonary Infiltrates Observed on Computed Tomography-Based Image Guidance for Radiotherapy Warrant Diagnostic Workup for Coronavirus Disease 2019227
Letter to the Editor About Huber et al.221
Decoding the Clinical and Molecular Signatures of EGFR Common, Compound, and Uncommon Mutations in NSCLC: A Brief Report209
Anti–Vascular Endothelial Growth Factor/Programmed Cell Death Protein 1 Bispecific Antibodies: Using Nunchucks to Fight an Old Adversary204
Prospective Cohort Study to Compare Long-Term Lung Cancer-Specific and All-Cause Survival of Clinical Early Stage (T1a–b; ≤20 mm) NSCLC Treated by Stereotactic Body Radiation Therapy and Surgery191
Editorial Commentary: Baseline Radiomic Signature to Estimate Overall Survival in Patients With NSCLC183
Board of Directors178
“Tumor-free survival” Does Not Outweigh the Adverse Effects of Anti-EGFR Therapy and Chemotherapy in Patients With NSCLC169
A Response to the Letter to the Editor: “Prognostic Factors for Survival After Thymoma Distant Recurrence Resection”168
Table of Contents162
Editorial Comment: Validation Study for the N Descriptor of the Newly Proposed 9th Edition of the TNM Staging System Proposed by the International Association for the Study of Lung Cancer158
Tobacco News Update—From the IASLC Tobacco Control Committee154
Letter Regarding “Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRASG12C-Mutated NSCLC Treated With Sotorasib”153
Response to Commentary on “EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate Innate Immune Evasion Through Up-Regulation of CD47”153
Board of Directors137
Predicted Effect of Incidental Pulmonary Nodule Findings on NSCLC Mortality126
DSTYK Inhibition Sensitizes NSCLC to Taxane-Based Chemotherapy125
Reducing pERKs to Break “RAS”istance to Sotorasib124
In This Issue114
Tobacco News Update—From the IASLC Tobacco Control Committee114
Meeting Announcements111
A Response to the Letter to the Editor: Safety Implications of Switching Pembrolizumab Dosage From 200 mg Every 3 Weeks to 400 mg Every 6 Weeks in Patients With Advanced NSCLC110
Table of Contents108
Suggestions for Improving the Comprehensive Characterization of Lung Pleomorphic Carcinoma106
Future Radiation Oncology: The Role of Personalization and Standardization in Stereotactic Body Radiotherapy103
Board of Directors102
Table of Contents101
In This Issue97
PP01.67 Evaluating immune-related adverse events (irAEs) in a real-world cohort with lung cancer receiving immunotherapy96
Editorial Board96
PP01.109 Concordance of Breast Density Between Low-Dose CT and Mammogram94
PP01.112 Treatment Patterns and Outcomes in Second-Line Advanced NSCLC Treated After Prior Platinum Chemotherapy and Immunotherapy Combination Therapy: A Real-World Study94
PP01.18 Real-world evaluation of racial and socioeconomic disparities in patients with NSCLC treated with immunotherapy93
OA01.01 Beamion LUNG-1: Phase Ia/b Trial of HER2 Tyrosine Kinase Inhibitor Zongertinib (BI 1810631) in Patients with HER2 Aberration-Positive Solid Tumors91
PP01.85 A Phase 2/3 Study of Fianlimab, Cemiplimab, plus Chemotherapy Versus Cemiplimab plus Chemotherapy in First-Line Advanced Non-Small Cell Lung Cancer87
PP01.172 It's Never Too Late To Quit83
PP01.117 Real-World Effectiveness and Safety Profile of Lurbinectedin and Other Second-Line Treatments in Small Cell Lung Cancer83
PPD01.02 Repotrectinib in Patients With ROS1 Fusion-Positive (ROS1+) NSCLC: Update From the Pivotal Phase 1/2 TRIDENT-1 Trial83
PP01.40 Treatment Patterns and Survival Outcomes of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer Survival at a Safety-Net Hospital80
PP01.101 Estimated Cost of Adverse Events and Surgery for Resectable Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Nivolumab Plus Platinum-Doublet Chemotherapy79
PP01.65 Efficacy and Safety of Dose-Escalated Alectinib in Patients with Metastatic ALK-positive NSCLC and CNS Relapse on Standard Dose Alectinib78
PPD01.06 Sacituzumab Govitecan + Pembrolizumab in 1L Metastatic Non–Small Cell Lung Cancer: Preliminary Results of the EVOKE-2 Study77
PP01.23 Plasma cell-free RNA PD-L1 or Tissue PD-L1 Protein Expression and Immunotherapy Outcomes in Advanced Non-Small Cell Lung Cancer76
PP01.06 Role of number of pathologic N2 stations for future AJCC lung cancer staging versions75
PP01.136 Understanding Experiences of Cancer-Related Fatigue in Patients with Lung Cancer After Their Cancer Treatment: A Qualitative Content Analysis74
PP01.119 Real-World Use of Lurbinectedin in Patients with Small Cell Lung Cancer: Jazz EMERGE 402 Updated Analysis74
PP01.169 Promotion of Low-Dose Computed Tomography Screening and Blood Biomarkers in Minority Communities for Early Detection of Lung Cancer in Northern Illinois72
PP01.74 LiquidHALLMARK detects more tissue-confirmed guideline-recommended biomarkers than Guardant360 for lung cancer: a prospective multicenter study72
PP01.90 Real-world Demographics, Clinical Characteristics, Treatment Patterns and Clinical Outcomes for US Patients with Limited-Stage SCLC (LS-SCLC)71
PP01.26 Proprietary vs Open-Source Radiomic Platform for Lung Cancer Diagnosis71
PP01.20 Hospitalization patterns for immune-related adverse events in patients with NSCLC treated with immunotherapy vs chemo-immunotherapy70
PP01.108 Trial in Progress: Shared Decision-Making Encounter Tool for Adjuvant Treatment of Lung Cancer: Randomized Control Trial68
PP01.135 Outcomes and Treatment Patterns for Recurrence following Concurrent Chemoradiation and Consolidation Immunotherapy in Unresectable Stage III NSCLC: A Multi-Center Study67
EP08.02-061 Treatment Sequences in ALK-rearranged Non-small Cell Lung Cancer; What Happens in the Real World?66
EP08.02-076 Efficacy and Safety Evaluations of Anlotinib in Patients with Advanced Non-small Cell Lung Cancer Treated with Bevacizumab66
EP08.02-077 Two Phase III Trials of Aumolertinib Plus Chemotherapy for NSCLC with EGFR and Concomitant non-EGFR Driver Genes /Tumor Suppressor Genes65
P54.05 Stereotactic Radiotherapy for Brain Metastases in Patients With Lung Cancer: Cyberknife Experience65
EP08.02-080 EGFR Testing Practices, Treatment Choice and Clinical Outcomes in Advanced NSCLC in a Real-World Setting64
0.11009383201599